Established 1999
     
8,000 companies from USA and India.  
   
Search over 25,500 news articles and 8,000 companies earnings    
 
Earnings Calls: 
Schering-Plough Third Quarter Earnings Call
Author: Maclintosh Kuhlengisa
123jump.com
Last Update: 7:58 AM EST December 10 2007
123Jump:


(Continued)

Email article | Print article

The global science-based health care company reported a 9% increase in sales to $2.8 billion, from $2.6 billion in the prior year reflecting continued sales growth across each of the customer segments. The firm continues to invest strongly in R&D and other critical areas to drive further growth for the long-term. In order to maintain the growth momentum, the firm plans to combine with Organon BioSciences are at an advanced stage.

Investors Question and Answers

 
 Company Website Links:
Investor Relations Financial Info Corporate / History Profile Executives Products Services
 
You need to upgrade your Flash Player


You need to upgrade your Flash Player

 
Carrie Cox: We are delighted that as new therapies are being developed for Hepatitis C treatment, PEGINTRON combination therapy will continue to be the backbone of therapy, and it will be background therapy in the addition of any new regimens that come to market. The patent situation for PEGINTRON in the US is expected to have extended exclusivity until 2018 to 2020.

Catherine Arnold (Credit Suisse): How soon after the Organon deal closure, are you going to come out on topics like Sugammadex and Organon''s pipeline?

Fred Hassan: We will use an initial opportunity to share with you the financial reporting aspects of the transaction, and there is complexity with all the changes that have occurred in recent years.

We will share with you the assessment that we will have of the R&D portfolio, as well as the marketed product portfolio and what we plan to do.
  1  2  3 More: Earnings Calls

 
 
Sources: Data collected by 123jump.com and Ticker.com from company press releases, filings and corporate websites.
Market data: BATS Exchange. Inc.
350 Fund Managers Interviews - 10-year Annual earnings on 4,600 U.S. companies - 20-quarter Earnings on 3,800 U.S. companies - 3,200 U.S. IPO Prospectuses
- 2,100 Economic data releases from U.S., EU, UK, India, HK and Australia. 10-year Annual reports on 3,500 U.S. companies -
U.S. Earnings Calendar with 4,800 companies - 90,000 10-K reports - 26,000 Global markets news archive - 2,200 Earnings Conference Call Summaries
Other Sites:
© 1999-2012 123jump.com. All rights reserved